Keyphrases
Response Predictors
100%
Response Rate
100%
Multiple Myeloma
100%
Multiple Myeloma Patients
100%
Humoral Response
100%
BNT162b2
100%
COVID-19 Vaccine
100%
COVID-19
42%
Low Response
28%
BNT162b2 Vaccine
28%
Smoldering multiple Myeloma
28%
Healthy Volunteers
14%
Old Age
14%
Multivariate Analysis
14%
Grade 12
14%
Clinically Significant
14%
Novel Agents
14%
Single Center
14%
Adverse Events
14%
Excess Risk
14%
Titer
14%
Treatment Type
14%
Myeloma
14%
Effective Rate of Protection
14%
Therapy-related
14%
Serological Response
14%
Hypogammaglobulinemia
14%
Seropositivity Rate
14%
Daratumumab
14%
Heavily Pretreated Patients
14%
Disease-related
14%
Patient-independent
14%
Biochemistry, Genetics and Molecular Biology
Messenger RNA
100%
Humoral Immunity
100%
Titer
50%
Multivariate Analysis
50%
Prospective Study
50%
Population
50%
Normal Human
50%
Immunology and Microbiology
Vaccine Efficacy
100%
Humoral Immunity
100%
Multiple Myeloma
100%
Smoldering Multiple Myeloma
22%
Seropositivity
11%
Titer
11%
Population
11%
Normal Human
11%
Hypogammaglobulinemia
11%
Daratumumab
11%
Medicine and Dentistry
Multiple Myeloma
100%
Humoral Immunity
100%
Smouldering Myeloma
22%
Disease
11%
Multivariate Analysis
11%
Volunteer
11%
Infection
11%
Population
11%
Prospective Study
11%
Adverse Event
11%
Myeloma
11%
Hypogammaglobulinemia
11%
Daratumumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Smoldering Multiple Myeloma
22%
Normal Human
11%
Prospective Study
11%
Infection
11%
Adverse Event
11%
Immunoglobulin Deficiency
11%
Myeloma
11%
Daratumumab
11%
Disease
11%